Since the last decade, two different treatment concepts are available for targeted therapy, BRAF ± MEK inhibition [15, 16], and immune checkpoint blockade [17, 18], which confirmed a survival benefit for advanced melanoma patients [14]. This evidence concerns the gene BRAF and melanoma.